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PRACTICE
Sustained Release Myofascial Release as 
Treatment for a Patient with Complications of 
Rheumatoid Arthritis and Collagenous Colitis:  
A Case Report
Background: Myofascial release (MFR) is a 
manual therapeutic technique used to release 
fascial restrictions, which may cause neuromus-
culoskeletal and systemic pathology.
Purpose: This case report describes the use of 
sustained release MFR techniques in a patient 
with a primary diagnosis of rheumatoid arthritis 
(RA) and a secondary diagnosis of collagenous 
colitis. Changes in pain, cervical range of mo-
tion, fatigue, and gastrointestinal tract function, 
as well as the impact of RA on daily activities, 
were assessed.
Methods: A 54-year-old white woman pre-
sented with signs and symptoms attributed to 
RA and collagenous colitis. Pre and post mea-
surements were taken with each treatment and 
during the interim between the initial and final 
treatment series. The patient recorded changes 
in pain, fatigue, gastrointestinal tract function, 
and quality of life. Cervical range of motion was 
assessed. Six sustained release MFR treatment 
sessions were provided over a 2-week period. Fol-
lowing an 8-week interim, two more treatments 
were performed.
Results: The patient showed improvements 
in pain, fatigue, gastrointestinal tract function, 
cervical range of motion, and quality of life fol-
lowing the initial treatment series of six sessions. 
The patient maintained positive gains for 5 weeks 
following the final treatment, after which her 
symptoms returned to near baseline measure-
ments. Following two more treatments, positive 
gains were achieved once again.
Conclusions: In a patient with RA and collag-
enous colitis, the application of sustained release 
MFR techniques in addition to standard medical 
treatment may provide short-term and long-term 
improvements in comorbid symptoms and overall 
quality of life.
KEYWORDS: Myofascial release, rheumatoid ar-
thritis, inflammatory bowel disease, manual therapy
INTRODUCTION
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic, 
polyarticular inflammatory disease, causing destruc-
tion and inflammation to the capsule and synovial 
lining of joints throughout the body.(1,2) The local 
inflammatory injury is induced by pathological im-
mune complexes traveling through the circulatory 
system.(1) T-lymphocytes, leukocytes, monocytes, 
and cytokines infiltrate the synovial fluid causing 
joint inflammation.(1) Tumor necrosis factor, a pri-
mary cytokine in RA, stimulates protein-degrading 
enzymes to be released.(1) This results in destruction 
of articular cartilage, bone resorption, and inhibition 
of bone formation.(1) Another pathological immune 
complex, rheumatoid factor, is an antibody that may 
trigger inflammatory reactions if it interacts with 
immunoglobulin antibodies and the mediators of 
inflammation.(1,3) This reaction, along with special-
ized effector cells, causes pannus tissue, a destruc-
tive vascular granulation tissue, to be formed.(1) As 
a result, degraded cartilage and bone, effusion of the 
joint capsule, and thickening of the capsule’s synovial 
lining occur.(1,3) These changes prevent the synovial 
joints from being lubricated and providing nutrition 
to the articular cartilage.(1) Pain, swelling, and gradual 
destruction of the joint can result in loss of function, 
deformity, and, ultimately, disability.(1,3) 
RA usually develops in the third or fourth decade of 
life, affecting three times more women than men.(1,2) 
The autoimmune inflammatory disease primarily af-
fects the synovial joints, especially the knees, hands, 
and feet.(2) The progressive development of RA can 
lead to prolonged morning stiffness, limited range of 
motion (ROM), symmetrical joint deformity, liga-
mentous laxity, altered biomechanics and posture, 
rheumatoid nodules, pain, fatigue, malaise, fever, 
weight loss, neurological compromise, and decreased 
quality of life.(1,2,4,5) As it is an autoimmune disorder, 
the cardiovascular, pulmonary, and gastrointestinal 
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(Gi) systems may also be affected.(1) This chronic, 
progressive disease goes through periods of remission 
and exacerbation.(1) understanding the pathophysi-
ology of RA has led to various treatment strategies 
including physical therapy, anti-inflammatory medi-
cations, disease-modifying antirheumatic drugs, im-
munosuppressants, and surgery.(4) Sustained release 
myofascial release (MFR) is also reported to be a 
valuable healing catalyst that may enable improve-
ments in these realms for individuals with RA.(6)
individuals with RA may have an excess of hu-
man tumor necrosis factor-alpha (TNF-α) causing 
the body’s immune system to attack healthy tissue.
(7) Treatment options for individuals with excess 
TNF-α include administering anti-TNF antibodies to 
reduce inflammation and joint damage.(2) Anti-TNF 
therapy assists in the treatment of RA by restoring 
the patient’s immune cells and hemoglobin, and 
reducing the patient’s rheumatoid factor levels, cy-
tokine production, vascular endothelial growth factor, 
acute-phase protein production, elevated platelets, 
and elevated fibrinogen.(2)
infliximab infusion (Remicade) is one type of anti-
TNF therapy for patients with moderate to severely 
active RA.(7) infliximab binds to TNF-α, interfering 
with endogenous TNF-α activity.(7) Specifically, this 
interference prevents inflammatory cytokine and 
tissue-degrading enzyme induction, leukocyte mi-
gration, and neutrophil and eosinophil activation.(7) 
Thus, infliximab reduces the infiltration of inflamma-
tory cells and mediates cellular adhesions.(7) These 
actions may prevent RA-associated joint disease and 
allow diseased joints to heal.(7) Maintenance dosing 
occurs at 4- to 8-week intervals, depending on the 
individual’s response to the medication.(7)
Another antirheumatic treatment is methotrexate, 
an immunosuppressant that inhibits the production of 
T cells.(2) Methotrexate is considered one of the most 
effective medications for RA, as it decreases pain and 
morning stiffness.(1) An effective treatment for RA has 
been the combination of infliximab with methotrex-
ate, creating a synergistic effect.(2) This combination 
has been shown to stop cartilage and bone damage 
in 50% of patients after 6 months of treatment, with 
effects lasting for 2 years.(2) 
Inflammatory Bowel Disease
inflammatory bowel disease (ibD) is a chronic 
inflammatory disease of the Gi tract that is classified 
as a functional disorder of motility in the small and 
large intestines. Common ibDs include ulcerative 
colitis and Crohn’s disease, while less common di-
agnoses include forms of microscopic colitis such 
as collagenous colitis and lymphocytic colitis.(8) ul-
cerative colitis displays chronic inflammation in the 
mucosa and submucosa of the colon, whereas chronic 
inflammation from Crohn’s disease can affect any 
part of the intestinal tract.(1) Microscopic colitis is a 
chronic inflammatory disease of the colon that causes 
chronic watery diarrhea.(9) Collagenous colitis causes 
thickened subepithelial collagen in the colon, whereas 
lymphocytic colitis has an increase in intraepithelial 
lymphocytes in the colorectal mucosa.(8,9) 
Though the etiology is unknown, ibD may result 
from genetic predisposition, environmental factors, 
immunologic factors, chronic stress, inflammation, 
and/or infection.(1,10) While both genders are equally 
affected by most ibD forms, collagenous colitis is 
predominantly found in females.(1,8,9) Common signs 
and symptoms include abdominal pain, constipation, 
diarrhea, rectal bleeding, decreased appetite, nausea, 
vomiting, and weight loss.(10) it is also suggested 
that ibD may share pathogenic pathways with other 
autoimmune diseases;(1,8,11) 40% of individuals with 
collagenous colitis also have autoimmune diseases 
such as RA.(12,13) Extraintestinal signs and symptoms 
signifying coexistent ibD and autoimmune diseases 
include chronic fatigue, fever, night sweats, skin 
lesions, uveitis, arthritis, migratory arthralgias, and 
hip pain.(1,10) 
ibD displays periods of exacerbation and remis-
sion.(1) The signs and symptoms of ibD during these 
exacerbation periods can negatively affect a person’s 
quality of life. Current treatment options for ibD 
include relieving abdominal pain, stabilizing motil-
ity, altering diet and nutrition, and altering lifestyle 
habits.(1) Pharmacological intervention has included 
antidiarrheals, antispasmodics, immune modifiers, 
antibiotics, corticosteroids, and aminosalicylates.(1) 
Similar to the treatment of RA, methotrexate and 
cytokine-based medications, such as infliximab, are 
being used to control inflammation in patients with 
ibD.(1,2,7) Little research has been conducted on 
the positive effects of combined pharmacological 
and complementary therapies and on the outcomes 
of using complementary therapies on the somatic 
symptoms of ibD.
Fascial System and Myofascial Release
The fascial system is a protective three-dimen-
sional web matrix of connective tissue that envelops 
every muscle, organ, gland, and cell in the body, also 
surrounding the circulatory system, nervous system, 
musculoskeletal system, and digestive tract to affect 
the overall shape of the body.(14) There are 12 dif-
ferent fascias or connective tissues in the body, each 
with varying concentrations of collagen, elastin, and 
ground substance.(15) Collagen provides support, 
shape, and stability; elastin allows for flexibility; 
ground substance cushions every cell.(16) The pres-
ence of smooth muscle cells within fascia, along with 
widespread presence of myelinated and unmyelinated 
sensory and motor nerve fibers and capillaries, has led 
to a hypothesis that fascia is an actively adapting or-
gan with functional importance, rather than a passive 
structural organ alone.(14) Fascia may contribute by 3
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assisting in support, protection, cellular respiration, 
elimination, metabolism, and fluid and lymphatic 
flow.(17) As a result, physiological and mechanical 
trauma to fascia at the cellular level may have an 
effect on posture, cellular health, and the immune 
system.(6,17–19) There is an important physiological 
interaction between fascia and the extracellular ma-
trix on the one hand and various cells of the body on 
the other.(17) “Without the oscillatory activity of the 
matrix and parenchymal cells, [cellular] metabolism 
would be stunted or nonexistent.” (17) 
it is hypothesized that fascial restrictions occur 
when fascia reorganizes itself in response to tension 
and stress.(6,20,21) Fascial restrictions constrict the 
tissue that is embedded within it, pulling on bones, 
tendons, and ligaments in an attempt to protect the 
body from further damage.(6,20–22) As a result, cellular 
function is disrupted and tremendous strain is placed 
on soft tissue, as demonstrated by injury, stress, sur-
gical adhesions, scars, inflammatory processes, and 
anatomical malalignments.(6,18,20–22) 
Mechanistic, also referred to as traditional or osteo-
pathic, MFR is used most often synonymously with 
soft tissue mobilization where the “individual ‘stroke’ 
or technique on a particular spot of tissue is between 
a few seconds and 1 ½ minutes.”(21,23,24) Sustained 
release MFR as taught by barnes emphasizes the 
intention to practice sustained pressure and traction 
over the fascial restriction for a minimum of 3–5 min-
utes to facilitate the piezoelectric effect to the crystal 
matrix of fascia.(16,20,21,25) When ground substance in 
a fascial restriction becomes more solid and less fluid, 
the piezoelectric effect is stifled and the energetic 
flow is impeded.(16,25) Electrical impulses are gener-
ated in the collagen by compressive and distraction 
forces within the musculoskeletal system.(20,25) These 
impulses trigger a cascade of cellular, biomechanical, 
neural, and extracellular events as the body adapts 
to external stress.(20,25) in response to internal stress, 
components of the extracellular fluid change in po-
larity and charge, affecting fascial motion.(20,25) The 
stimulation of the gel ground substance of the fascia 
requires this sustained pressure over time in order 
to bring about the “melting” of the colloidal part of 
the tissue and to stimulate a sustained piezoelectric 
flow of electrons along the tissue, thus maximizing 
the “energy” flow to the tissue over a longer period 
of time.(6,25,26) Further, with the extracellular matrix 
softening and the fascial restriction releasing, pres-
sure on pain-sensitive tissue is relieved and the tis-
sues are rehydrated to allow for conduction of flow 
of photons and vibration.(25,27) However, Schleip(24) 
reports that any change in the tissue felt under the 
hands cannot be attributed either to a softening of the 
ground substance, termed thixotropy, or to a response 
to the electron flow from the piezoelectric effect 
as described by Oschman(16) because of laboratory 
studies of time and force dependency of connective 
tissue plasticity.(21,28,29) Schleip suggests that fascial 
plasticity may be due to the self-regulatory qualities 
of the client’s nervous system.(24) Health care provid-
ers have used MFR in this way in the clinical setting 
for many years, but evidence beyond case reports, 
such as randomized and case–control clinical trials, 
is lacking.
Purpose
The presentation of combined symptoms of RA and 
ibD has led to the investigation of further potential 
therapeutic options. Complementary therapies, such 
as MFR, are designed to restore homeostasis by re-
lieving restrictions that impede energetic flow, work 
with the body’s own healing mechanism, and have the 
possibility of being an effective adjunct to allopathic 
treatments.(6) This case report describes the changes 
in ROM, pain, fatigue, and Gi tract function follow-
ing the use of MFR techniques on a patient with a 
primary diagnosis of RA and a secondary diagnosis 
of collagenous colitis. The guiding questions were 
as follows: Does MFR, administered by three prac-
titioners in six 45-minute treatment sessions over a 
period of 2 weeks, affect cervical ROM and reported 
pain, fatigue, Gi tract function, and quality of life in 
a patient with RA and collagenous colitis? How long 
could these changes potentially persist following the 
last treatment? 
METHODS
Patient History and Review of Systems
A 54-year-old white woman presented with cervi-
cal pain, systemic pain, fatigue, and explosive diar-
rhea due to a primary diagnosis of RA and a secondary 
diagnosis of collagenous colitis. Over the past 8 years 
she received infliximab infusions and chiropractic 
adjustments to address the cervical and systemic 
pain. None of these treatments resulted in sustained 
relief longer than a few days. Five years after she 
started receiving infliximab infusions, collagenous 
colitis was diagnosed. Her gastroenterologist was 
astounded that the collagenous colitis presented af-
ter receiving infliximab infusions for several years, 
as that pharmacological treatment is used to control 
inflammation with ibD. During the course of this 
study, the patient did not receive chiropractic care, 
only infliximab infusions.
Initial Interview
The patient reported a dull ache in the right elbow, 
neck, and both temporomandibular joints. She stated 
that both knees, especially the left, felt achy. As a 
result of her knee pain, she was unable to wear high 
heels. She expressed frustration, as she was unable 
to run or rollerblade and was restricted to a limited 4
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amount of walking. She was able to swim the breast-
stroke as long as her neck was not in pain. basic 
activities of daily living were adversely affected, 
including exiting the bathtub from a long-sitting 
position. She noted difficulty with intricate needle-
work for crocheting and was unable to complete 
computer-related tasks due to bilateral wrist pain. 
She reported numbness in her right third and fourth 
fingers and a flexion contracture of the left third 
finger. She napped on a daily basis, with an overall 
feeling of fatigue. Her “normal” Gi tract function 
consisted of nausea, bowel urgency, and explosive 
diarrhea, but she did not experience this on the day 
of the initial interview.
Physical Examination and Imaging
The postural assessment revealed slight head rota-
tion to the right, slight elevation of the right shoulder, 
increased lordosis of the lumbar spine, and anterior 
rotation of the left ileum. Cervical disk degeneration 
was noted through x-ray imaging. She had full hip 
and shoulder ROM, but cervical ROM was limited 
in all directions.
Initial Values
Preceding the first treatment, the patient rated 
cervical pain as 3.6/10 and systemic pain as 4.8/10. 
Cervical ROM values were as follows: flexion: chin-
to-chest (chin-to-chest was considered full flexion); 
extension: 44°; right rotation: 52°; left rotation: 40°; 
right lateral flexion: 22°; and left lateral flexion: 19° 
(Table 1). She rated her fatigue as 1.1/10 in the morn-
ing, 3.3/10 in the afternoon, 5.1/10 in the evening, and 
5.7/10 with activity (Figure 1). She scored 164 out of 
a possible 433 on the Arthritis impact Measurement 
Scales 2 (AiMS2; Appendix Table 1).
Examination
To measure progress, data collected at each treat-
ment and at periodic intervals between treatments 
included cervical ROM (goniometry), cervical and 
systemic pain (visual analog scale), and fatigue (P4 
instrument).(30) Gi tract function was revealed through 
patient report. The AiMS2 and the Complementary 
and Alternative Medicine (CAM) Methods Question-
naire were provided(31) (personal communication, C 
Ritenbaugh, PhD, MPH, June 28, 2009).
P4 Instrument
The P4 instrument was originally created to cap-
ture changes in pain throughout the day. However, 
Ta b l e  1.  Summary of Cervical Range of Motiona
Initial treatment series
 
Interim
Final treatment 
series
 
 
Interview
 
Post second 
treatment
 
Post fifth  
treatment
 
 
2 Weeks
 
 
5 Weeks
8 Weeks/final 
treatment series 
interview
 
Post first  
treatment
Cervical flexion Chin-to- 
chest
Chin-to- 
chest
Chin-to- 
chest
Chin-to-
chest
Chin-to-
chest
Chin-to- 
chest
Chin-to- 
chest
Cervical extension 44° 36° 55° 42° 46° 34° 49°
Right cervical rotation 52° 45° 56° 60° 65° 42° 59°
Left cervical rotation 40° 40° 54° 45° 45° 32° 40°
Right cervical lateral 
flexion
22° 31° 30° 30° 32° 28° 26°
Left cervical lateral 
flexion
19° 16° 25° 24° 31° 16° 24°
a Range of motion as measured with a goniometer during first treatment series, interim, and second treatment series. All measurements were 
taken before the patient received myofascial release on that day. At the eighth week interim following the initial treatment series, the physical 
therapist decided to perform the final treatment series.
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and activity fatigue. Overall fatigue was alleviated with myofascial 
release by the last treatment session of the initial treatment series. 
The fatigue started to return 5 weeks after the last treatment series 
and was more severe by 8 weeks. After the final treatment series, 
the fatigue was eliminated again.
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for the purpose of this study, the original instrument 
was adapted to capture changes in fatigue. in the 
adapted version, the word “fatigue” replaced “pain.” 
The patient provided data on morning, afternoon, 
evening, and activity-related fatigue. The questions 
were answered by placing a mark along a visual ana-
logue scale from zero to 10, signifying none to worst 
possible fatigue.(30)
Arthritis Impact Measurement Scales 2
The AiMS2 was designed to assess the impact of 
arthritis on daily life. items assessed included physical 
function, emotional status, and overall arthritis impact 
on daily life in the past month. Possible scores ranged 
from 74 to 433; lower scores indicated wellness and 
higher scores indicated greater impact of arthritis 
upon daily life.(31)
CAM Methods Questionnaire
The CAM Methods Questionnaire, in a trial phase 
during the study, was designed to help understand the 
patient’s experiences throughout in the study. Written 
quotes were used as well as checked items to quan-
tify changes over time (personal communication, C 
Ritenbaugh, PhD, MPH, June 28, 2009).
Intervention
it is hypothesized that MFR is designed to pro-
vide more space in the fascia, thereby attempting to 
relieve pressure on pain-sensitive tissue and improve 
flow of immune system components, lymphatic fluid, 
blood, neurotransmitters, neuropeptides, steroids, and 
digestive enzymes.(16) The MFR technique begins 
with a postural examination and palpation for fascial 
restrictions.(26) Then, gentle sustained pressure is used 
with the hands placed on the restricted tissue, in the 
direction of the restriction.(26) The pressure is sustained 
over the skin, without allowing the hands to slide, for 
a minimum of 90–120 seconds to allow the tissue to 
begin to release.(26) Once the release begins, pressure 
is maintained while the therapists’ hands follow the 
direction of the fascial release.(26) Sustained releases 
are held for a minimum of 3–5 minutes (Table 2).(26)
The purpose of this treatment approach was to 
potentially increase energy levels, decrease pain, and 
stabilize Gi motility to enhance the overall quality of 
life. Six initial treatments were performed in 2 weeks’ 
time, followed by an interim of 8 weeks, after which 
a final treatment series of two sessions was provided. 
Treatment sessions were provided by a physical thera-
pist experienced in MFR techniques and two trained 
assistants. Each session was performed for 45 minutes 
and consisted of several techniques, including manual 
cervical traction, transverse plane releases, arm and 
leg pulls, and cross-hand techniques.(26)
RESULTS
The following summary describes changes in signs 
and symptoms over time. Data collected from each 
treatment were compared with the most recent values. 
Post treatment is defined as the timeframe from the 
conclusion of the last treatment session to the initia-
tion of the next treatment session.
Initial Treatment Series
Post first treatment: stabilization in Gi tract func-
tion (Table 3), systemic pain (Figure 2), and cervical 
pain (Figure 3). in the 2 days following the first MFR 
ap p e n d i x  T a b l e  1.  Progression of Arthritis impact Measurement 
Scales 2 (AiMS2) Scoresa
initial treatment series
interview 164
initial treatment series
Post fifth treatment 124
initial treatment series
Post sixth treatment/interim 2 weeks 124
interim 5 weeks 116
interim 8 weeks/final treatment series
interview 155
a  The AiMS2 was used to measure changes in the patient’s global 
health, pain, mobility, and social function with arthritis. The possible 
scores ranged from 74-433 with lower scores indicating a better qual-
ity of life. The patient demonstrated a better quality of life during 
and up to 5 weeks after the last initial treatment session. However, 
the patient’s quality of life regressed to previous levels between 5 
and 8 weeks after the last treatment session. A correlation may exist 
between myofascial release and quality of life.
Ta b l e  2.  Summary of a Typical Sustained Release Myofascial 
Release Treatment Sessiona
Pelvic wedging
Occipital condyle release
bilateral lower extremity traction
Transverse plane over left knee
Transverse plane over thoracic inlet
Transverse plane over lower intestine
Gentle massage over cervical muscles
Pectoral release
Right arm pull
Left arm pull
Sternal release caudally with cervical traction
Left sternocleidomastoid release
Right sternocleidomastoid release
Energy release over left foot nodule
a A typical myofascial release treatment session was conducted for 
45 minutes by 3 practitioners. Each release was held for a minimum 
of 3–5 minutes using gentle sustained pressure in the direction of 
the restriction.6
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treatment, the patient reported less fatigue than at 
any other time that she could remember in the past 8 
years. Her pain had decreased such that she did not 
consider taking pain medications in the morning and 
was able to work at the computer for more than 1 
hour. She reported improved sleep at night and was 
once again able to wear high heels without left knee 
pain. Gi tract function remained stable, as she did not 
experience any episodes of diarrhea. 
Post second treatment: improved Gi tract function 
(Table 3) and cervical pain (Figure 3); varied cervi-
cal ROM (Table 1). Following the second treatment 
session, she stated she was able to walk for at least 
20 minutes pain-free. Gi tract function continued to 
improve based on her subjective report of no bouts 
of diarrhea or urgency.
Post third treatment: improved Gi tract function 
(Table 3), systemic pain (Figure 2), and cervical pain 
(Figure 3). On the day of the third MFR session, she 
received an infliximab infusion. She noted that Gi 
tract function had improved, and she was able to eat 
all foods without having urgency or diarrhea. She 
noted that she felt her posture was “straighter” and 
that her “head [sat] on top of [her] shoulders.”
Post fourth treatment: improved Gi tract function 
(Table 3), systemic pain (Figure 2), cervical pain 
(Figure 3), and fatigue (Figure 1). She was “astounded 
by the effects of MFR,” and expressed again that she 
hadn’t felt this energized in years. At the end of her 
session, her cervical and systemic pain had decreased 
to 1.3/10 and 0.8/10, respectively.
Post fifth treatment: improved Gi tract function 
(Table 3), systemic pain (Figure 2), cervical pain (Fig-
ure 3), cervical ROM (Table 1), AiMS2 (Appendix 
Table 1), and quality of life. She noted her fatigue 
level reached zero. She no longer napped during the 
afternoons, nor did she use an alarm clock. All Gi 
tract symptoms were eliminated, except for urgency 
following consumption of coffee. The AiMS2 score 
Ta b l e  3.  Summary of Subjective Gastrointestinal Reporta
Time of study Symptom
initial treatment series
interview No diarrhea
Post first treatment No diarrhea; no interference with sleep
Post second treatment Seminormal bowel movement
Post third treatment No diarrhea; no interference with sleep; no urgency
Post fourth treatment No diarrhea; no abdominal pain
Post fifth treatment Diarrhea only following coffee; normal bowel schedule
Post sixth treatment/interim 2 weeks Normal bowel movement; discharge from gastroenterologist for 6 months
interim 5 weeks Slightly loose stools; no cramps or abdominal pain
interim 8 weeks/final treatment series interview Explosive diarrhea
Final treatment series post first treatment Semisolid stools
a  The patient reported having explosive diarrhea prior to seeking complimentary therapy. Return to semisolid stools following an additional 
treatment session suggests that sustained release myofascial release may help normalize bowel movements.
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FI g u r e  2.  Systemic pain (visual analog scale): comparison of pre 
and post treatment. Systemic pain was reduced during the initial 
treatment series and returned during the interim period between 
the initial and final treatment series. Pain was reduced once again 
in the final treatment series.
FI g u r e  3.  Cervical pain (visual analog scale): comparison of 
pre and post treatment. The graph depicts a decrease in cervical 
pain from before each treatment to immediately after each 
treatment. Cervical pain decreased in the initial treatment series 
and remained at approximately the same level through the fifth 
week after the last treatment session of the initial treatment series. 
Pain was decreased again following one additional myofascial 
release treatment.
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decreased from 164 to 124. in the CAM Methods 
Questionnaire, she recorded a change in energy from 
4/10 prior to the study to currently 10/10 and stated 
that she “felt [herself] coming back to life now with 
more energy.” She also recorded changes in physical 
health (pre: 5/10, post: 8.5/10) and happiness (pre: 
8.5/10, post: 10/10). 
Posttreatment Follow-Up 
Post sixth treatment; interim, 2 weeks following 
initial treatment series: improvement maintained in 
Gi tract function (Table 3), systemic pain (Figure 2), 
cervical pain (Figure 3), and fatigue (Figure 1); main-
tenance of AiMS2 (Appendix Table 1) and quality of 
life; varied cervical ROM (Table 1). She returned for 
an examination 2 weeks following her last treatment 
to reveal that many of the positive results had been 
maintained. Her gastroenterologist discharged her for 
the next 6 months due to regular bowel movements. 
She recorded changes in energy (pre: 2.5/10, post: 
10/10), physical health (pre: 7/10, post: 8/10), and 
happiness (pre: 10/10, post: 10/10). She felt she was 
“on a path towards health and wellness” and that her 
“life [was] getting back to normal.” 
interim, 5 weeks following initial treatment 
series: improved cervical ROM (Table 1), AiMS2 
(Appendix Table 1), and quality of life; regression 
in Gi tract function (Table 3), systemic pain (Figure 
2), and cervical pain (Figure 3). The AiMS2 score 
decreased from 124 to 116. Changes in energy (pre: 
1.5/10, post: 10/10), physical health (pre: 5/10, post: 
9/10), and happiness (pre: 7.5/10, post: 9.5/10) were 
recorded through the CAM Methods Questionnaire. 
She stated that “the fatigue is gone!” and was “us-
ing [her] inner resources to heal [herself].” Gi tract 
function maintained relative stability, with reports of 
slightly loose stools, which may have been a result 
of a change in daily vitamin intake. 
interim, 8 weeks following initial treatment series: 
regression in Gi tract function (Table 3), systemic 
pain (Figure 2), cervical pain (Figure 3), cervical 
ROM (Table 1), fatigue (Figure 1), AiMS2 (Appendix 
Table 1), and quality of life. Eight weeks following 
the last treatment she was reevaluated. AiMS2 score 
increased from 116 to 155 indicating the collagenous 
colitis symptoms had returned approximately 6 weeks 
after the last treatment session. She also stated that 
“although [her] pain is about the same as it was before 
the study, it doesn’t matter as much any more because 
[she] knows [she] will get better again.” in the CAM 
Methods Questionnaire, she recorded the changes in 
energy as pre 2/10, post 2.5/10 and in physical health 
as pre 2.5/10, post 4.5/10.
Final Treatment Series
Given her regressing status, the patient received 
MFR on the day of her week 8 follow-up appointment, 
initiating a second round of treatments. She returned 
3 days later and reported that the “sludge [wasn’t] 
there.” Her Gi symptoms went from explosive diar-
rhea to semisolid stools (Table 3). And, although she 
still experienced mild pain on occasion, she expressed 
that she felt better equipped to handle the pain now 
that she was not fatigued (Figure 1).
Final values: on the second treatment day during 
the second round of treatments, she rated cervical pain 
as pre 0.4/10, post 0.3/10 (Figure 3) and systemic pain 
as pre 2.4/10, post 0.4/10) (Figure 2). She rated all 
fatigue as zero (Figure 1). Her cervical ROM was as 
follows: flexion: chin-to-chest; extension: 49°; right 
rotation: 59°; left rotation: 40°; right lateral flexion: 
26°; and left lateral flexion: 24° (Table 1).
Summary 
When compared with the initial evaluation and the 
subsequent eight treatments of the entire 11-week 
study, the patient showed improvements in cervical 
and systemic pain. Cervical flexion was maintained 
throughout the study. Left rotation, while variable 
throughout the study, had the same value at baseline 
and the final treatment session. The ranges in all other 
cervical motions improved from the initial evaluation. 
She reported complete alleviation of fatigue and Gi 
symptoms. She maintained positive gains up to 5 
weeks following the final treatment of the initial treat-
ment series. However, over a stressful weekend, her 
symptoms returned to near baseline measurements. 
At this point, 8 weeks after the initial treatment series 
ended, the patient received two additional treatments 
of MFR 3 days apart. immediately following these 
two treatments, similar gains were achieved again. 
DISCUSSION
This case study was designed to study how MFR 
may influence an individual with a diagnosis of com-
plications from RA and collagenous colitis. Sustained 
release MFR in conjunction with allopathic treatment 
appeared to relieve pain and fatigue, increase cervi-
cal ROM, and improve Gi tract function for up to 5 
weeks following a 2-week treatment series. When the 
patient regressed after the initial treatment series, two 
additional treatments of MFR were provided, achiev-
ing positive results.
This case study had several limitations. While the 
patient reported that she was symptom-free at the 
initial evaluation, she reported improvements in her 
Gi tract function after the second treatment. This is 
believed to be due to a remission episode on the day 
of the initial evaluation. Also, it was learned that the 
method chosen to quantify changes in cervical ROM 
had not been validated to quantify movement of the 
multiaxial cervical spine. in future studies, it would 
be appropriate to select a goniometer validated to 8
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measure cervical ROM. The P4 instrument, originally 
created to capture changes in pain throughout the day, 
and modified in this study to assess changes in fatigue, 
had not been validated for this purpose. At the time 
of the study, the CAM Methods Questionnaire had 
not been validated. Thus, the results of the question-
naire are not validated. However, the results from the 
CAM Methods Questionnaire were supplemented 
with written quotes from the patient. Additionally, 
the AiMS2 and CAM Methods Questionnaire were 
not administered following the final treatment series. 
After the sixth treatment session, it was believed that 
the study would be complete, with the patient having 
periodic follow-up to determine the length of time that 
positive gains would be sustained. After the patient 
regressed during follow-up, the final treatment series 
was administered to provide patient relief, and not 
intended to be included this study. Given the rapid 
reversal of negative signs and symptoms and the 
reemergence of positive gains, it was decided to in-
clude these two sessions in this case report, though a 
thorough follow-up after the final treatment series was 
not conducted. Further, it was believed that a stress-
ful weekend caused the patient to return to baseline 
measurements, indicating that stress provokes this 
patient’s symptoms. However, the patient could have 
had her symptoms return as a result of the relapsing–
remitting conditions of RA. Finally, it is also possible 
that the patient gained improvements during the course 
of the case study secondary to receiving an infliximab 
infusion on the day of the third treatment session.
Future studies could be more comprehensive if 
the effects of MFR on joint integrity were captured. 
A comparison of radiographs before and after treat-
ment may signify the positive effects of MFR on 
joint ROM and posture. Having a control patient not 
receiving infliximab infusions would be ideal, since 
the medication may reduce signs and symptoms as-
sociated with RA and ibD. 
The results from this case study suggest that the 
integration of sustained release MFR and standard 
medical treatment may facilitate improvements in 
pain, ROM, fatigue, and Gi motility resulting in an 
improved quality of life. With the limited evidence-
based research on MFR, this case report has discussed 
how this complementary therapy may be beneficial. 
Manual therapists may wish to consider sustained 
release MFR as a valuable treatment approach for 
individuals with RA, ibD, chronic fatigue, movement 
limitations, or pain. it may be a useful complemen-
tary therapy for patients who have tried conventional 
treatments without success.
ACKNOWLEDGMENTS
The authors would like to thank Sherrill H. Hayes 
for her ongoing support, kathryn E. Roach and irene 
McEwen for their thoughtful critique, and Polestar 
Physical Therapy & Pilates Center for the use of their 
facility and equipment.
CONFLICT OF INTEREST NOTIFICATION
The authors received coverage of expenses or re-
imbursements for travel and accommodation of less 
than $1,000 each for airfare and hotel expenses for 
the 2009 CSM Conference.
Carol M. Davis was a paid teacher with Rehabilita-
tion Services, inc. providing instruction in myofascial 
release as continuing education.
This case study was presented as a poster presen-
tation at the 2009 CSM Conference in Las Vegas, 
Nevada, and the abstract was published in the Journal 
of Women’s Health Physical Therapy.
COPYRIGHT
Published under the CreativeCommons Attribution-
NonCommercial-NoDerivs 3.0 License.
REFERENCES
  1.  Goodman CC, boissonnault WG, Fuller kS. Pathology: Impli-
cations for the Physical Therapist. 2nd ed. Philadelphia, PA: 
Saunders; 2003:646–650,946–954.
  2.  Feldmann M. Development of anti-TNF therapy for rheumatoid 
arthritis. Nat Rev Immunol. 2002;2(5):364–371.
  3.  boers M. Pathophysiology of rheumatoid arthritis: split or 
lump? Arthritis Rheum. 2008;58(10):2925–2927.
  4.  Silber JS, Verma Rb, Greenberg AS. Rheumatoid arthritis of 
the cervical spine. Neurosurg Q. 2006;16(1): 1–8.
  5.  Fukase M, koizumi F, Wakaki k. Histopathologic analysis 
of 16 subcutaneous rheumatoid nodules. Acta Pathol Jpn. 
1980;30:871–882.
  6.  barnes JF. Myofascial release: the missing link in traditional 
treatment. in: Davis CM. Complementary Therapies in Re-
habilitation: Evidence for Efficacy in Therapy, Prevention, 
and Wellness. 3rd ed. Thorofare, NJ: Slack incorporated; 
2008:89–112.
  7.  Remicade® [package insert]. Malvern, PA: Centocor; 2008. 
  8.  Giardiello FM, Lazenby AJ, Yardley JH, et al. increased HLA 
A1 and diminished HLA A3 in lymphocytic colitis compared 
to controls and patients with collagenous colitis. Dig Dis Sci. 
1992;37(4):496–499.
  9.  Saul SH. The watery diarrhea-colitis syndrome: a review of 
collagenous and microscopic/lymphocytic colitis. Int J Surg 
Pathol. 1993;1(1):65–82.
  10.  Goodman CC, Snyder Tk. Differential Diagnosis for Physi-
cal Therapists: Screening for Referral. 4th ed. St Louis, MO: 
Saunders; 2006:392–393.
  11.  Cohen R, Robinson D, Paramore C, et al. Autoimmune 
disease concomitance among inflammatory bowel disease 
patients in the united States, 2001-2002. Inflamm Bowel Dis. 
2008;14(6):738–743. 9
In t e r n a t I o n a l Jo u r n a l  o f  th e r a p e u t I c Ma s s a g e a n d  Bo d y w o r k —Vo l u M e  4, nu M B e r 3, se p t e M B e r 2011
CubiCk ET AL. : SuSTAiNED RELEASE MYOFASCiAL RELEASE
  12.  Chande N, Driman Dk, Reynolds RP. Collagenous colitis 
and lymphocytic colitis: patient characteristics and clinical 
presentation. Scand J Gastroenterol. 2005;40(3):343–347.
  13.  Székely H, Pónyai G, Temesvári E, et al. Association of col-
lagenous colitis with prurigo nodularis. Eur J Gastroenterol 
Hepatol. 2009;21(8):946–951.
  14.  Schleip R. Fascial plasticity: a new neurobiological explanation. 
Part 2. J Bodyw Mov Ther. 2003;7(2):104–116.
  15.  Langevin HM, Huijing PA. Communicating about fascia: 
history, pitfalls, and recommendations. Int J Ther Massage 
Bodywork. 2009;2(4):3–8. 
  16.  Oschman JL. Energy Medicine: The Scientific Basis. Edinburgh: 
Churchill Livingstone; 2000:55,170–171.
  17.  Lee RP. The living matrix: a model for the primary respiratory 
mechanism. Explore (NY). 2008;4(6):374–378.
  18.  Pischinger A. The Extracellular Matrix and Ground Regulation: 
Basis for a Holistic Biological Medicine. berkeley, CA: North 
Atlantic books; 2007:179.
  19.  Rolf iP. Rolfing: The Integration of Human Structures. Santa 
Monica, CA: Dennis-Landman; 1977.
  20.  O’Connell JA. bioelectric responsiveness of fascia: a model 
for understanding the effects of manipulation. Tech Orthop. 
2003;18(1):67–73.
  21.  Threlkeld AJ. The effects of manual therapy on connective 
tissue. Phys Ther. 1992;72(12):893–902.
  22.  Fuss Fk. Anatomy of the cruciate ligaments and their function 
in extension and flexion of the human knee joint. Am J Anat. 
1989;184(2):165–176.
  23.  barnes MF. Myofascial release: morphological change in the 
connective tissue. in: Charman RA. Complementary Therapies 
for Physical Therapists. Woburn, MA: butterworth-Heine-
mann; 2000:175.
  24.  Schleip R. Fascial plasticity: a new neurobiological explanation. 
Part 1. J Bodyw Mov Ther. 2003;7(1):11–19.
  25.  Davis CM. Doerger C, Rowland J, et al. Myofascial release as 
complementary in physical therapy for two elderly patients with 
osteoporosis and kyphoscoliosis: two case studies [abstract]. J 
Geriatr Phys Ther. 2002;25(3):33.
  26.  barnes JF, Marzano A. Myofascial Release: The Search for 
Excellence. Paoli, PA: Rehabilitation Services; 1990:37,56–57, 
75,122,125–133.
  27.  Twomey L, Taylor J. Flexion, creep, dysfunction and hyster-
esis in the lumbar vertebral column. Spine (Phila Pa 1976). 
1982;7(2):116–122.
  28.  Currier DP, Nelson RM. Dynamics of Human Biologic Tissues. 
Philadelphia, PA: F.A. Davis; 1992.
  29.  Juhan D. Job’s Body. barrytown, NY: Station Hill Press; 1987.
  30.  Spadoni GF, Stratford PW, Solomon PE, et al. The evaluation 
of change in pain intensity: a comparison of the P4 and single-
item numeric pain rating scales. J Orthop Sports Phys Ther. 
2004;34(4):187–193.
  31.  Meenan RF, Mason JH, Anderson JJ, et al. AiMS2: the content 
and properties of a revised and expanded arthritis impact mea-
surement scales health status questionnaire. Arthritis Rheum. 
1992;35(1):1–10.
Corresponding author: Erin E. Cubick, PT, DPT, 
LAT, ATC, CSCS, c/o Carol M. Davis, PT, DPT, 
EdD, MS, FAPTA Department of Physical Therapy, 
university of Miami, 5915 Ponce de Leon blvd., 5th 
Floor, Coral Gables, FL 33146-2435 uSA.
E-mail: erin.cubick@gmail.com